All In Biotech

Drug Trial Radar · NCT03606174

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

260

Actual

Start

Sep 11, 2018

Primary completion

Aug 3, 2022

Study completion Aug 22, 2022

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Conditions

  • Urothelial Carcinoma
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Ureter
  • Urothelial Carcinoma of the Renal Pelvis and Ureter
  • Urothelial Carcinoma Urethra

Interventions

  • SitravatinibDrug

    Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases

  • NivolumabDrug

    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

  • PembrolizumabDrug

    Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody

  • Enfortumab vedotinDrug

    Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 3 years

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • University of California Irvine

    Irvine, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • SCRI - Florida Cancer Specialists- North Region

    St. Petersburg, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • SCRI - Florida Cancer Specialists - West Palm Beach

    West Palm Beach, Florida

  • The University of Chicago

    Chicago, Illinois

  • Indiana University - Melvin & Bren Simon Cancer Center

    Indianapolis, Indiana

  • Norton Cancer Institute - Broadway

    Louisville, Kentucky

  • Ochsner Cancer Institute

    New Orleans, Louisiana

  • Maryland Oncology Hematology, P.A.

    Lanham, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • GU Research Network/Urology Cancer Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada - Southwest

    Las Vegas, Nevada

  • New York Oncology Hematology - Albany Medical Center

    Albany, New York

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Northwell Health Monter Cancer Center

    Lake Success, New York

  • NYU Langone Laura & Isaac Perlmutter Cancer Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • New York-Presbyterian - Weill Cornell Medical Center

    New York, New York

  • University of North Carolina - Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Duke University Hospital

    Durham, North Carolina

  • The Ohio State University College of Medicine

    Columbus, Ohio

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Vanderbilt University - Ingram Cancer Center

    Nashville, Tennessee

  • Texas Oncology-Austin Central

    Austin, Texas

  • Texas Oncology- Memorial City

    Houston, Texas

  • University of Texas - MD Anderson Cancer Center

    Houston, Texas

  • University of Texas Health Science Center

    San Antonio, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • Virginia Cancer Specialists- Fairfax

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Seattle Cancer Center Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.